Synthetic siRNA market shows significant growth potential

Growth rate of 9 percent is pro­jected for the next year.

ARLINGTON, Va.—A new report from BioInformatics, LLC, Optimizing Synthetic RNAi: Perspectives from the Pharmaceutical & Biotech Industry, finds that while the use of synthetic siRNA is still relative­ly new, the industrial market seg­ment will continue strong growth over the near term. Among current industrial users of siRNA, an over­all growth rate of 9 percent is pro­jected for the next twelve months. In addition, about one-third of survey respondents indicate that they do not now conduct RNAi experiments but plan to do so in the upcoming months, implying further market growth potential.
 
"Clearly, synthetic siRNA is a vital tool in facilitating pharmaceu­tical and biotech research," says Dr. Tamara Zemlo, director of syn­dicated research at BioInformatics. "Of the survey respondents, only 6 percent do not use and have no plans to use synthetic siRNA. The extent of RNAi's appeal is also striking. The report features the opinions of researchers from almost 90 different companies."
 
The report presents synthetic siRNA brand share based on usage rates and relative expenditure. This data are expected to help sup­pliers understand their position in what is essentially a two-tier mar­ket, as the top four suppliers com­mand more than 75 percent of the industrial market's brand share. For these synthetic siRNA provid­ers, the report features their Net Promoter Score (NPS) rankings, an important measure of "active" brand loyalty.
 
"Strikingly, we found that the majority of respondents would not recommend their preferred suppli­er," Zemlo notes. "This ties direct­ly to respondents' willingness to consider switching their sup­plier of synthetic siRNA. Almost all respondents stated that they could be convinced to try another supplier's product—if the prod­uct performed exceptionally on an attribute deemed important to the scientist. Since approximately half of respondents use only one supplier, successfully encourag­ing researchers to switch suppliers would greatly affect siRNA market share."
 
Results presented in this study focus on brand health of the top suppliers based on product pro­motion, product attractiveness, product price, product placement and supplier customer service and technical support. According to BioInformatics, service, per­formance and product availabil­ity seem to distinguish the mar­ket leader—Dharmacon—from its closest competitors: Invitrogen, Qiagen and Ambion. Behind the leaders are a number of suppli­ers, including Proligo, Integrated DNA Technologies, MWG Biotech, Bioneer, OligoEngine and B-Bridge.


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue